Aurora Cannabis Inc. ( ACB Quick Quote ACB - Free Report) is scheduled to report first-quarter fiscal 2021 results on Nov 9, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 56.7%. Q1 Estimates
For the fiscal first quarter, the Zacks Consensus Estimate for the bottom line is pegged at a loss of 25 cents per share.
Factors to Note
With the production and sale of cannabis been considered as essential services across Canada and Europe, the company is likely to have witnessed sustained consumer cannabis sales with the help of online ordering and home delivery. This, in turn, is likely to have benefited Aurora Cannabis’ fiscal first-quarter performance.
Ongoing improvement in the company’s production cash cost per gram might get reflected in gross margin on cannabis net revenues in the fiscal first quarter.
The company may have gained from its low cost per unit production, thereby aiding in creating a brand across multiple pricing tiers while delivering robust and sustainable margins.
Also, Aurora Cannabis is likely to have exhibited favorable results in its domestic and international medical businesses in the fiscal first quarter driven by continued investments in these businesses. Additionally, the company has been leveraging its coast-to-coast supply agreements to provide a wide range of premium consumer products throughout Canada. Moreover, it remains committed toward serving medical patients with sustained supply of premium products. These factors may have contributed to medical cannabis sales in the to-be-reported quarter. In February, the company received the EU GMP (European Union Good Manufacturing Practices) certification of its Aurora River facility with a run rate of around 30,000 kilograms annually, which will allow the company to allocate significantly higher volume of products for export markets as and when they develop. This may have favored the fiscal first-quarter performance. Aurora Cannabis has been selectively collaborating with a number of organizations, developing inventory and prioritizing its resources to make sure that consumers across Canada have access to its high-quality derivative products including edibles, vapes and infused beverages. This might have aided the to-be-reported quarter’s performance. Here’s What the Quantitative Model Suggests
Per our proven model, the combination of a positive
Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is the case here. Earnings ESP: Aurora Cannabis has an Earnings ESP of +7.37%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Zacks Rank: The company carries a Zacks Rank #3. Other Stocks Worth a Look
Here are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this quarter.
SeaSpine Holdings Corporation ( SPNE Quick Quote SPNE - Free Report) has an Earnings ESP of +6.67% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here. Corbus Pharmaceuticals Holdings, Inc. ( CRBP Quick Quote CRBP - Free Report) has an Earnings ESP of +17.07% and a Zacks Rank of 3. Medtronic plc ( MDT Quick Quote MDT - Free Report) has an Earnings ESP of +0.97% and a Zacks Rank of 3. 5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >>